TradeFlare's AI research teams analysed ORIC on 6 market nights between July 28, 2026 and September 4, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 4, 2026 | HOLD | $12.74 | — / — | -1.6% | -2.9% | Awaiting clearer technical signals or a stronger fundamental catalyst. |
| August 11, 2026 | HOLD | $13.50 | — / — | +1.4% | -9.0% | Continued positive drift post-earnings gap. |
| August 10, 2026 | HOLD | $13.50 | — / — | -1.8% | -7.3% | Continued positive drift post-earnings gap. |
| August 4, 2026 | BUY | $10.60 | $12.77 / $9.00 | +1.9% | -4.3% | The bullish fundamental and sentiment outlook suggests a medium-term upward trend, while the technical setup offers a near-term entry point. |
| July 29, 2026 | BUY | $11.91 | — / — | +14.6% | +23.3% | The scanner trigger suggests a short-term post-earnings drift opportunity. |
| July 28, 2026 | BUY | $12.02 | — / — | +13.1% | +16.1% | Continued positive clinical trial data for ORIC's prostate cancer drug. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.